12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Phase II data

Data from a Phase II trial in 22 patients showed that Revlimid plus rituximab produced an ORR of 64% after twelve 4-week cycles of treatment. Overall survival (OS) was 95%. In patients ages 65 and older, 71% achieved a response after...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >